Welcome Guest
Home » Press Releases » Antibody Drug Conjugates: Riding on the Second Growth Wave

Antibody Drug Conjugates: Riding on the Second Growth Wave


Published : Nov 20, 2017

Roots Analysis has announced the addition of Antibody Drug Conjugates Market (4th Edition), 2017-2030’ report to their list of offerings. The report features an extensive study on current landscape and the future outlook of the rapidly growing antibody drug conjugates market.

 

Ronit Sharma, the principal analyst stated that, “Since the first approval of MYLOTARG™ in 2000, and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. In the last seven years, the market has witnessed increasing interest from drug developers and healthcare investors alike. Post the commercialization of ADCETRIS® in 2011 and KADCYLA® in 2013, there was a temporary, but evident, decline in the popularity of ADCs. This was attributed to the fact that no new ADC candidates were approved after 2013 and the focus had shifted to other novel therapies, such as immune checkpoint inhibitors and T-cell therapies. However, the recent approval of BESPONSA® and re-approval of MYLOTARG™ has renewed the interest in the domain.”

 

The report presents an elaborate compilation of research, analysis and opinions on several key aspects of the market. Among other things, the report includes the following:

  • A discussion on the pipeline of ADCs along with information on the developers / technology providers, phase of development of candidate therapies, drug targets, therapeutic indications, and the types of linkers and payloads / warheads used.
  • Identification of the most commonly targeted therapeutic indications and details of the ADCs being developed against them. The study highlights the key epidemiological facts about the diseases and also lists the currently available treatment options.
  • Extensive review on the key opinion leaders (KOLs) in the field of ADCs; the report contains a detailed 2X2 analysis to assess the relative experience of certain KOLs. It also contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers.
  • An assessment of the various therapies that are being evaluated in combination with ADCs; the study also presents the likely evolution of these therapies across different therapeutic indications.
  • Elaborate profiles of clinical stage companies and their respective product portfolios; each profile features an overview of the company, its financial performance, product portfolio, and detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and clinical trial results).
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant agreements.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area. Moreover, the report features a detailed study on the various grants that have been awarded to research institutes in this field.
  • A review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations. This section also highlights the competition between contemporary technology platforms.
  • An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs. The study presents findings from various ADC studies in different animal models. The report presents an analysis of the different methods used in estimating FIH doses. In addition, it presents possible FIH starting doses and the estimated dose escalations required to reach human maximum tolerated dose (MTD).
  • A detailed analysis of the patents that have recently been filed related to ADCs. The study also highlights the emerging trends in innovation and identifies the key players involved. In addition, it presents a high-level view on the valuation of these patents.
  • A detailed case study on ADC contract manufacturers, highlighting the prevalent and emerging trends in ADC manufacturing.

 

Sharma further added, “While there are close to 200 ADCs in clinical / preclinical stages of development, the field is currently going through a gradual transition. The industry is shifting from relying on conventional technologies to newer approaches for generating ADCs. This transition has paved way for several well-funded start-ups, which offer novel conjugation approaches, more potent warheads and modified linker technologies. In addition, ADCs are now being evaluated in combination with several other novel therapies, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies.”

 

The report highlights the contributions of several players in the field; some of the examples are listed below:

  • Astellas Pharma / Agensys
  • AbbVie / Stemcentrx
  • Bayer HealthCare
  • Biotest Pharmaceuticals
  • Celldex Therapeutics
  • ImmunoGen
  • Immunomedics
  • Roche / Genentech
  • Pfizer
  • Progenics Pharmaceuticals
  • Sanofi
  • Seattle Genetics

 

The opinions and insights presented in the report were influenced by discussions with senior stakeholders in the industry. These include Alan Burnett (Professor, School of Medicine, James Cardiff University), Aldo Braca, (Chief Executive Officer, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix), Anonymous (Chief Executive Officer, Leading CMO), Christian Bailly (Head of CDMO, Pierre Fabre), Christian Rohlff, (Founder and CEO, Oxford BioTherapeutics), Anonymous (Director, Business Development, Leading CMO), John Burt (Chief Executive Officer, Abzena), Laurent Ducry (ADC R&D, Lonza), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Sasha Koniev (Chief Executive Officer, Syndivia), Stacy McDonald (Group Product Manager) and Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions).

For additional details, please visit

 

https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-4th-edition-2017-2030/180.html

 

or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

About Roots Analysis

Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at  This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Copyright © Roots Analysis. All Rights Reserved.
website security